{"id":35195,"date":"2025-07-09T13:27:17","date_gmt":"2025-07-09T17:27:17","guid":{"rendered":"https:\/\/joinastudy.ca\/?p=35195"},"modified":"2025-07-09T13:27:17","modified_gmt":"2025-07-09T17:27:17","slug":"new-dosing-for-lilly-alzheimers-drug-shows-safer-profile","status":"publish","type":"post","link":"https:\/\/joinastudy.ca\/fr\/new-dosing-for-lilly-alzheimers-drug-shows-safer-profile\/","title":{"rendered":"New Dosing for Lilly Alzheimer’s Drug Shows Safer Profile"},"content":{"rendered":"

The FDA has approved a safer dosing schedule for Eli Lilly\u2019s Alzheimer\u2019s drug, Kisunla<\/strong>, which could make it more appealing to doctors and patients. The updated schedule reduces the risk of a serious side effect called ARIA-E\u2014brain swelling caused by anti-amyloid drugs.<\/p>\n

Originally, Kisunla was given in higher doses early on. Now, the drug will be introduced more slowly. Patients will start with one vial, then increase to two, three, and finally four vials over several months, still taken every four weeks. This gradual increase lowered ARIA-E risk by up to 41% in a clinical study called Trailblazer-Alz6.<\/p>\n

By week 24, only 14% of patients on the new regimen experienced ARIA-E compared to 24% on the original. After a year, the rates were 16% and 25%, respectively. Importantly, no one on the new regimen developed severe ARIA-E, while two people did on the original plan.<\/p>\n

Despite the lower risk, the new schedule didn\u2019t weaken the drug\u2019s main effect: reducing amyloid plaques in the brain. Patients still saw about a 67% drop in these plaques, similar to the original dosing group.<\/p>\n

However, the study didn\u2019t find much difference in another side effect, ARIA-H, which involves brain bleeding. A larger trial would be needed to determine that risk more clearly.<\/p>\n

Sales of Kisunla have been slow, with just $21.5 million in early 2025. Experts say safety concerns and complex diagnosis methods have made doctors hesitant. A new FDA-approved blood test for Alzheimer\u2019s may help, but it could take time to make an impact.<\/p>\n

Researchers are now watching a major trial, Trailblazer-Alz3, which is testing Kisunla in people who show brain changes but no symptoms. Results from this trial could change how Alzheimer\u2019s is treated in the future.<\/p>\n

To read more on this topic, click here<\/strong><\/a>.<\/p>\n","protected":false},"excerpt":{"rendered":"

The FDA has approved a safer dosing schedule for Eli Lilly\u2019s Alzheimer\u2019s drug, Kisunla, which could make it more appealing to doctors and patients. The updated schedule reduces the risk of a serious side effect called ARIA-E\u2014brain swelling caused by anti-amyloid drugs. Originally, Kisunla was given in higher doses early on. Now, the drug will<\/p>\n","protected":false},"author":964,"featured_media":5459,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[600,487,488,489,513],"tags":[],"class_list":["post-35195","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-alzheimers-dementia","category-drug-development","category-health-canada-fda","category-industry-news","category-health-and-wellness","category-600","category-487","category-488","category-489","category-513","description-off"],"acf":[],"yoast_head":"\nNew Dosing for Lilly Alzheimer's Drug Shows Safer Profile - JoinAStudy.ca<\/title>\n<meta name=\"description\" content=\"The FDA has approved a safer dosing schedule for Eli Lilly\u2019s Alzheimer\u2019s drug, Kisunla, which could make it more appealing to doctors and patients.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/joinastudy.ca\/fr\/new-dosing-for-lilly-alzheimers-drug-shows-safer-profile\/\" \/>\n<meta property=\"og:locale\" content=\"fr_FR\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"New Dosing for Lilly Alzheimer's Drug Shows Safer Profile\" \/>\n<meta property=\"og:description\" content=\"The FDA has approved a safer dosing schedule for Eli Lilly\u2019s Alzheimer\u2019s drug, Kisunla, which could make it more appealing to doctors and patients.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/joinastudy.ca\/fr\/new-dosing-for-lilly-alzheimers-drug-shows-safer-profile\/\" \/>\n<meta property=\"og:site_name\" content=\"JoinAStudy.ca\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/joinastudy.ca\" \/>\n<meta property=\"article:published_time\" content=\"2025-07-09T17:27:17+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/joinastudy.ca\/wp-content\/uploads\/ADHereditary_1.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"1200\" \/>\n\t<meta property=\"og:image:height\" content=\"800\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"JoinAStudy Team\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@JoinAStudy_ca\" \/>\n<meta name=\"twitter:site\" content=\"@JoinAStudy_ca\" \/>\n<meta name=\"twitter:label1\" content=\"\u00c9crit par\" \/>\n\t<meta name=\"twitter:data1\" content=\"JoinAStudy Team\" \/>\n\t<meta name=\"twitter:label2\" content=\"Dur\u00e9e de lecture estim\u00e9e\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/joinastudy.ca\\\/fr\\\/new-dosing-for-lilly-alzheimers-drug-shows-safer-profile\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/joinastudy.ca\\\/fr\\\/new-dosing-for-lilly-alzheimers-drug-shows-safer-profile\\\/\"},\"author\":{\"name\":\"JoinAStudy Team\",\"@id\":\"https:\\\/\\\/joinastudy.ca\\\/fr\\\/#\\\/schema\\\/person\\\/da824a10716e724d72676ec94d865d71\"},\"headline\":\"New Dosing for Lilly Alzheimer’s Drug Shows Safer Profile\",\"datePublished\":\"2025-07-09T17:27:17+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/joinastudy.ca\\\/fr\\\/new-dosing-for-lilly-alzheimers-drug-shows-safer-profile\\\/\"},\"wordCount\":302,\"publisher\":{\"@id\":\"https:\\\/\\\/joinastudy.ca\\\/fr\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/joinastudy.ca\\\/fr\\\/new-dosing-for-lilly-alzheimers-drug-shows-safer-profile\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/joinastudy.ca\\\/wp-content\\\/uploads\\\/ADHereditary_1.jpg\",\"articleSection\":[\"Alzheimer\u2019s & Dementia\",\"Drug Development\",\"Health Canada & FDA\",\"Industry News\",\"Health and Wellness\"],\"inLanguage\":\"fr-FR\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/joinastudy.ca\\\/fr\\\/new-dosing-for-lilly-alzheimers-drug-shows-safer-profile\\\/\",\"url\":\"https:\\\/\\\/joinastudy.ca\\\/fr\\\/new-dosing-for-lilly-alzheimers-drug-shows-safer-profile\\\/\",\"name\":\"New Dosing for Lilly Alzheimer's Drug Shows Safer Profile - JoinAStudy.ca\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/joinastudy.ca\\\/fr\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/joinastudy.ca\\\/fr\\\/new-dosing-for-lilly-alzheimers-drug-shows-safer-profile\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/joinastudy.ca\\\/fr\\\/new-dosing-for-lilly-alzheimers-drug-shows-safer-profile\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/joinastudy.ca\\\/wp-content\\\/uploads\\\/ADHereditary_1.jpg\",\"datePublished\":\"2025-07-09T17:27:17+00:00\",\"description\":\"The FDA has approved a safer dosing schedule for Eli Lilly\u2019s Alzheimer\u2019s drug, Kisunla, which could make it more appealing to doctors and patients.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/joinastudy.ca\\\/fr\\\/new-dosing-for-lilly-alzheimers-drug-shows-safer-profile\\\/#breadcrumb\"},\"inLanguage\":\"fr-FR\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/joinastudy.ca\\\/fr\\\/new-dosing-for-lilly-alzheimers-drug-shows-safer-profile\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\\\/\\\/joinastudy.ca\\\/fr\\\/new-dosing-for-lilly-alzheimers-drug-shows-safer-profile\\\/#primaryimage\",\"url\":\"https:\\\/\\\/joinastudy.ca\\\/wp-content\\\/uploads\\\/ADHereditary_1.jpg\",\"contentUrl\":\"https:\\\/\\\/joinastudy.ca\\\/wp-content\\\/uploads\\\/ADHereditary_1.jpg\",\"width\":1200,\"height\":800,\"caption\":\"Is Alzheimer disease hereditary? Are you at risk? Learn more about the genes linked to Alzheimer and if you're at risk.\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/joinastudy.ca\\\/fr\\\/new-dosing-for-lilly-alzheimers-drug-shows-safer-profile\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/joinastudy.ca\\\/fr\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"New Dosing for Lilly Alzheimer’s Drug Shows Safer Profile\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/joinastudy.ca\\\/fr\\\/#website\",\"url\":\"https:\\\/\\\/joinastudy.ca\\\/fr\\\/\",\"name\":\"JoinAStudy.ca\",\"description\":\"JoinAStudy.ca - Help create a healthier future\",\"publisher\":{\"@id\":\"https:\\\/\\\/joinastudy.ca\\\/fr\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/joinastudy.ca\\\/fr\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"fr-FR\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/joinastudy.ca\\\/fr\\\/#organization\",\"name\":\"JoinAStudy.ca\",\"url\":\"https:\\\/\\\/joinastudy.ca\\\/fr\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\\\/\\\/joinastudy.ca\\\/fr\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/joinastudy.ca\\\/wp-content\\\/uploads\\\/JoinaStudy-Logo-Mobile-e1520526932796.png\",\"contentUrl\":\"https:\\\/\\\/joinastudy.ca\\\/wp-content\\\/uploads\\\/JoinaStudy-Logo-Mobile-e1520526932796.png\",\"width\":118,\"height\":65,\"caption\":\"JoinAStudy.ca\"},\"image\":{\"@id\":\"https:\\\/\\\/joinastudy.ca\\\/fr\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/joinastudy.ca\",\"https:\\\/\\\/x.com\\\/JoinAStudy_ca\",\"https:\\\/\\\/www.youtube.com\\\/channel\\\/UC_ed0XmzH5ImSNOEJcdXKqg\"],\"publishingPrinciples\":\"https:\\\/\\\/joinastudy.ca\\\/why-join-a-study\\\/\",\"ownershipFundingInfo\":\"https:\\\/\\\/joinastudy.ca\\\/information-disclaimer\\\/\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/joinastudy.ca\\\/fr\\\/#\\\/schema\\\/person\\\/da824a10716e724d72676ec94d865d71\",\"name\":\"JoinAStudy Team\",\"url\":\"https:\\\/\\\/joinastudy.ca\\\/fr\\\/author\\\/grant\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"New Dosing for Lilly Alzheimer's Drug Shows Safer Profile - JoinAStudy.ca","description":"The FDA has approved a safer dosing schedule for Eli Lilly\u2019s Alzheimer\u2019s drug, Kisunla, which could make it more appealing to doctors and patients.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/joinastudy.ca\/fr\/new-dosing-for-lilly-alzheimers-drug-shows-safer-profile\/","og_locale":"fr_FR","og_type":"article","og_title":"New Dosing for Lilly Alzheimer's Drug Shows Safer Profile","og_description":"The FDA has approved a safer dosing schedule for Eli Lilly\u2019s Alzheimer\u2019s drug, Kisunla, which could make it more appealing to doctors and patients.","og_url":"https:\/\/joinastudy.ca\/fr\/new-dosing-for-lilly-alzheimers-drug-shows-safer-profile\/","og_site_name":"JoinAStudy.ca","article_publisher":"https:\/\/www.facebook.com\/joinastudy.ca","article_published_time":"2025-07-09T17:27:17+00:00","og_image":[{"width":1200,"height":800,"url":"https:\/\/joinastudy.ca\/wp-content\/uploads\/ADHereditary_1.jpg","type":"image\/jpeg"}],"author":"JoinAStudy Team","twitter_card":"summary_large_image","twitter_creator":"@JoinAStudy_ca","twitter_site":"@JoinAStudy_ca","twitter_misc":{"\u00c9crit par":"JoinAStudy Team","Dur\u00e9e de lecture estim\u00e9e":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/joinastudy.ca\/fr\/new-dosing-for-lilly-alzheimers-drug-shows-safer-profile\/#article","isPartOf":{"@id":"https:\/\/joinastudy.ca\/fr\/new-dosing-for-lilly-alzheimers-drug-shows-safer-profile\/"},"author":{"name":"JoinAStudy Team","@id":"https:\/\/joinastudy.ca\/fr\/#\/schema\/person\/da824a10716e724d72676ec94d865d71"},"headline":"New Dosing for Lilly Alzheimer’s Drug Shows Safer Profile","datePublished":"2025-07-09T17:27:17+00:00","mainEntityOfPage":{"@id":"https:\/\/joinastudy.ca\/fr\/new-dosing-for-lilly-alzheimers-drug-shows-safer-profile\/"},"wordCount":302,"publisher":{"@id":"https:\/\/joinastudy.ca\/fr\/#organization"},"image":{"@id":"https:\/\/joinastudy.ca\/fr\/new-dosing-for-lilly-alzheimers-drug-shows-safer-profile\/#primaryimage"},"thumbnailUrl":"https:\/\/joinastudy.ca\/wp-content\/uploads\/ADHereditary_1.jpg","articleSection":["Alzheimer\u2019s & Dementia","Drug Development","Health Canada & FDA","Industry News","Health and Wellness"],"inLanguage":"fr-FR"},{"@type":"WebPage","@id":"https:\/\/joinastudy.ca\/fr\/new-dosing-for-lilly-alzheimers-drug-shows-safer-profile\/","url":"https:\/\/joinastudy.ca\/fr\/new-dosing-for-lilly-alzheimers-drug-shows-safer-profile\/","name":"New Dosing for Lilly Alzheimer's Drug Shows Safer Profile - JoinAStudy.ca","isPartOf":{"@id":"https:\/\/joinastudy.ca\/fr\/#website"},"primaryImageOfPage":{"@id":"https:\/\/joinastudy.ca\/fr\/new-dosing-for-lilly-alzheimers-drug-shows-safer-profile\/#primaryimage"},"image":{"@id":"https:\/\/joinastudy.ca\/fr\/new-dosing-for-lilly-alzheimers-drug-shows-safer-profile\/#primaryimage"},"thumbnailUrl":"https:\/\/joinastudy.ca\/wp-content\/uploads\/ADHereditary_1.jpg","datePublished":"2025-07-09T17:27:17+00:00","description":"The FDA has approved a safer dosing schedule for Eli Lilly\u2019s Alzheimer\u2019s drug, Kisunla, which could make it more appealing to doctors and patients.","breadcrumb":{"@id":"https:\/\/joinastudy.ca\/fr\/new-dosing-for-lilly-alzheimers-drug-shows-safer-profile\/#breadcrumb"},"inLanguage":"fr-FR","potentialAction":[{"@type":"ReadAction","target":["https:\/\/joinastudy.ca\/fr\/new-dosing-for-lilly-alzheimers-drug-shows-safer-profile\/"]}]},{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/joinastudy.ca\/fr\/new-dosing-for-lilly-alzheimers-drug-shows-safer-profile\/#primaryimage","url":"https:\/\/joinastudy.ca\/wp-content\/uploads\/ADHereditary_1.jpg","contentUrl":"https:\/\/joinastudy.ca\/wp-content\/uploads\/ADHereditary_1.jpg","width":1200,"height":800,"caption":"Is Alzheimer disease hereditary? Are you at risk? Learn more about the genes linked to Alzheimer and if you're at risk."},{"@type":"BreadcrumbList","@id":"https:\/\/joinastudy.ca\/fr\/new-dosing-for-lilly-alzheimers-drug-shows-safer-profile\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/joinastudy.ca\/fr\/"},{"@type":"ListItem","position":2,"name":"New Dosing for Lilly Alzheimer’s Drug Shows Safer Profile"}]},{"@type":"WebSite","@id":"https:\/\/joinastudy.ca\/fr\/#website","url":"https:\/\/joinastudy.ca\/fr\/","name":"JoinAStudy.ca","description":"JoinAStudy.ca - Help create a healthier future","publisher":{"@id":"https:\/\/joinastudy.ca\/fr\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/joinastudy.ca\/fr\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"fr-FR"},{"@type":"Organization","@id":"https:\/\/joinastudy.ca\/fr\/#organization","name":"JoinAStudy.ca","url":"https:\/\/joinastudy.ca\/fr\/","logo":{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/joinastudy.ca\/fr\/#\/schema\/logo\/image\/","url":"https:\/\/joinastudy.ca\/wp-content\/uploads\/JoinaStudy-Logo-Mobile-e1520526932796.png","contentUrl":"https:\/\/joinastudy.ca\/wp-content\/uploads\/JoinaStudy-Logo-Mobile-e1520526932796.png","width":118,"height":65,"caption":"JoinAStudy.ca"},"image":{"@id":"https:\/\/joinastudy.ca\/fr\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/joinastudy.ca","https:\/\/x.com\/JoinAStudy_ca","https:\/\/www.youtube.com\/channel\/UC_ed0XmzH5ImSNOEJcdXKqg"],"publishingPrinciples":"https:\/\/joinastudy.ca\/why-join-a-study\/","ownershipFundingInfo":"https:\/\/joinastudy.ca\/information-disclaimer\/"},{"@type":"Person","@id":"https:\/\/joinastudy.ca\/fr\/#\/schema\/person\/da824a10716e724d72676ec94d865d71","name":"JoinAStudy Team","url":"https:\/\/joinastudy.ca\/fr\/author\/grant\/"}]}},"_links":{"self":[{"href":"https:\/\/joinastudy.ca\/fr\/wp-json\/wp\/v2\/posts\/35195","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/joinastudy.ca\/fr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/joinastudy.ca\/fr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/joinastudy.ca\/fr\/wp-json\/wp\/v2\/users\/964"}],"replies":[{"embeddable":true,"href":"https:\/\/joinastudy.ca\/fr\/wp-json\/wp\/v2\/comments?post=35195"}],"version-history":[{"count":0,"href":"https:\/\/joinastudy.ca\/fr\/wp-json\/wp\/v2\/posts\/35195\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/joinastudy.ca\/fr\/wp-json\/wp\/v2\/media\/5459"}],"wp:attachment":[{"href":"https:\/\/joinastudy.ca\/fr\/wp-json\/wp\/v2\/media?parent=35195"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/joinastudy.ca\/fr\/wp-json\/wp\/v2\/categories?post=35195"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/joinastudy.ca\/fr\/wp-json\/wp\/v2\/tags?post=35195"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}